FidoCure® (YC W18) — FidoCure® is the leader in precision medicine for canine oncology
Cancer is a genetic disease. We know this from decades of human and veterinary cancer research.
FidoCure® is a Y Combinator company in the Winter 2018 batch. Its directory entry describes it as: FidoCure® is the leader in Precision Medicine for Canine Oncology. The founder listed is christina lopes (Founder) (Y Combinator directory entry, January 4, 2018).
Get an email when FidoCure® changes status, grows its team or files a funding notice. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
Cancer is a genetic disease. We know this from decades of human and veterinary cancer research. Precision medicine and targeted therapies are successfully used to treat humans with cancer. At FidoCure®, we bring this approach to the world of veterinary medicine.
FidoCure® empowers veterinarians to offer genetic sequencing and targeted therapies to treat dogs with cancer. We are committed to expanding the veterinary oncology toolbox for both diagnostics and therapeutics.
Our veterinary partners have treated thousands of dogs over the past 30 years and work closely with the growing FidoCure® network of over 143 clinics and 180 forward-thinking veterinary oncologists throughout the US.
Together, we can combat canine cancer!
christina lopes
Founder
Founders, titles and bios as the company published them. Photographs are our own copies of the ones on that record, so they do not break when the original link expires.
One of 74 companies held here in Healthcare › Healthcare Services.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
Want the whole picture on FidoCure®?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on FidoCure®: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on FidoCure® covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
You get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind FidoCure®: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
FidoCure® (YC W18) — FidoCure® is the leader in precision medicine for canine oncology. MentionFox, 2026-10-29. https://mentionfox.com/funding/yc-fidocure
